These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 27634194)

  • 1. Alternative core development around the tetracyclic indole class of HCV NS5A inhibitors.
    Tong L; Yu W; Coburn CA; Meinke PT; Nair AG; Dwyer MP; Chen L; Selyutin O; Rosenblum SB; Jiang Y; Fells J; Hu B; Zhong B; Soll RM; Liu R; Agrawal S; Xia E; Zhai Y; Kong R; Ingravallo P; Nomeir A; Asante-Appiah E; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Oct; 26(20):5132-5137. PubMed ID: 27634194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationships of proline modifications around the tetracyclic-indole class of NS5A inhibitors.
    Tong L; Yu W; Coburn CA; Chen L; Selyutin O; Zeng Q; Dwyer MP; Nair AG; Shankar BB; Kim SH; Yang DY; Rosenblum SB; Ruck RT; Davies IW; Hu B; Zhong B; Hao J; Ji T; Zan S; Liu R; Agrawal S; Carr D; Curry S; McMonagle P; Bystol K; Lahser F; Ingravallo P; Chen S; Asante-Appiah E; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Nov; 26(21):5354-5360. PubMed ID: 27680588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substituted tetracyclic indole core derivatives of HCV NS5A inhibitor MK-8742.
    Yu W; Zhou G; Coburn CA; Zeng Q; Tong L; Dwyer MP; Hu B; Zhong B; Hao J; Ji T; Zan S; Chen L; Mazzola R; Kim JH; Sha D; Selyutin O; Rosenblum SB; Lavey B; Nair AG; Heon Kim S; Keertikar KM; Rokosz L; Agrawal S; Liu R; Xia E; Zhai Y; Curry S; McMonagle P; Ingravallo P; Asante-Appiah E; Chen S; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Oct; 26(19):4851-4856. PubMed ID: 27568086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.
    Yu W; Coburn CA; Nair AG; Wong M; Tong L; Dwyer MP; Hu B; Zhong B; Hao J; Yang DY; Selyutin O; Jiang Y; Rosenblum SB; Kim SH; Lavey BJ; Zhou G; Rizvi R; Shankar BB; Zeng Q; Chen L; Agrawal S; Carr D; Rokosz L; Liu R; Curry S; McMonagle P; Ingravallo P; Lahser F; Asante-Appiah E; Nomeir A; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3800-5. PubMed ID: 27282742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aryl or heteroaryl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.
    Yu W; Coburn CA; Nair AG; Wong M; Rosenblum SB; Zhou G; Dwyer MP; Tong L; Hu B; Zhong B; Hao J; Ji T; Zan S; Kim SH; Zeng Q; Selyutin O; Chen L; Masse F; Agrawal S; Liu R; Xia E; Zhai Y; Curry S; McMonagle P; Ingravallo P; Asante-Appiah E; Lin M; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3414-20. PubMed ID: 27394665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matched and mixed cap derivatives in the tetracyclic indole class of HCV NS5A inhibitors.
    Dwyer MP; Keertikar KM; Chen L; Tong L; Selyutin O; Nair AG; Yu W; Zhou G; Lavey BJ; Yang DY; Wong M; Kim SH; Coburn CA; Rosenblum SB; Zeng Q; Jiang Y; Shankar BB; Rizvi R; Nomeir AA; Liu R; Agrawal S; Xia E; Kong R; Zhai Y; Ingravallo P; Asante-Appiah E; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Aug; 26(16):4106-11. PubMed ID: 27423481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity.
    Yu W; Coburn CA; Yang DY; Meinke PT; Wong M; Rosenblum SB; Chen KX; Njoroge GF; Chen L; Dwyer MP; Jiang Y; Nair AG; Selyutin O; Tong L; Zeng Q; Zhong B; Ji T; Hu B; Agrawal S; Xia E; Zhai Y; Liu R; Kong R; Ingravallo P; Asante-Appiah E; Nomeir A; Fells J; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Jul; 26(13):3158-3162. PubMed ID: 27180013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms.
    Tong L; Yu W; Chen L; Selyutin O; Dwyer MP; Nair AG; Mazzola R; Kim JH; Sha D; Yin J; Ruck RT; Davies IW; Hu B; Zhong B; Hao J; Ji T; Zan S; Liu R; Agrawal S; Xia E; Curry S; McMonagle P; Bystol K; Lahser F; Carr D; Rokosz L; Ingravallo P; Chen S; Feng KI; Cartwright M; Asante-Appiah E; Kozlowski JA
    J Med Chem; 2017 Jan; 60(1):290-306. PubMed ID: 27808515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity.
    Coburn CA; Meinke PT; Chang W; Fandozzi CM; Graham DJ; Hu B; Huang Q; Kargman S; Kozlowski J; Liu R; McCauley JA; Nomeir AA; Soll RM; Vacca JP; Wang D; Wu H; Zhong B; Olsen DB; Ludmerer SW
    ChemMedChem; 2013 Dec; 8(12):1930-40. PubMed ID: 24127258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Chromane Containing Hepatitis C Virus (HCV) NS5A Inhibitors with Improved Potency against Resistance-Associated Variants.
    Yu W; Tong L; Hu B; Zhong B; Hao J; Ji T; Zan S; Coburn CA; Selyutin O; Chen L; Rokosz L; Agrawal S; Liu R; Curry S; McMonagle P; Ingravallo P; Asante-Appiah E; Chen S; Kozlowski JA
    J Med Chem; 2016 Nov; 59(22):10228-10243. PubMed ID: 27792320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel pan-genotypic HCV NS5A inhibitors containing a novel tetracyclic core.
    Yu W; Hu B; Zhong B; Hao J; Lei Z; Agrawal S; Rokosz L; Liu R; Chen S; Asante-Appiah E; Kozlowski JA
    Bioorg Med Chem Lett; 2019 Mar; 29(5):700-706. PubMed ID: 30711390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
    Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
    Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of potent macrocyclic HCV NS5A inhibitors.
    Yu W; Vibulbhan B; Rosenblum SB; Martin GS; Vellekoop AS; Holst CL; Coburn CA; Wong M; Selyutin O; Ji T; Zhong B; Hu B; Chen L; Dwyer MP; Jiang Y; Nair AG; Tong L; Zeng Q; Agrawal S; Carr D; Rokosz L; Liu R; Curry S; McMonagle P; Ingravallo P; Lahser F; Asante-Appiah E; Fells J; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3793-9. PubMed ID: 27282743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of NS5A inhibitors containing diverse heteroaromatic cores.
    Henderson JA; Bilimoria D; Bubenik M; Cadilhac C; Cottrell KM; Denis F; Dietrich E; Ewing N; Falardeau G; Giroux S; L'Heureux L; Liu B; Mani N; Morris M; Nicolas O; Pereira OZ; Poisson C; Reddy TJ; Selliah S; Shawgo RS; Vaillancourt L; Wang J; Xu J; Chauret N; Berlioz-Seux F; Chan LC; Das SK; Grillot AL; Bennani YL; Maxwell JP
    Bioorg Med Chem Lett; 2015 Feb; 25(4):948-51. PubMed ID: 25577039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants.
    Gottwein JM; Pham LV; Mikkelsen LS; Ghanem L; Ramirez S; Scheel TKH; Carlsen THR; Bukh J
    Gastroenterology; 2018 Apr; 154(5):1435-1448. PubMed ID: 29274866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral activity and resistance of HCV NS5A replication complex inhibitors.
    Gao M
    Curr Opin Virol; 2013 Oct; 3(5):514-20. PubMed ID: 23896281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Research progress of HCV NS5A complex inhibitors].
    Jiang XB; Li YP; Li ZR
    Yao Xue Xue Bao; 2016 Sep; 51(9):1378-87. PubMed ID: 29924511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic Activity of Combined NS5A Inhibitors.
    O'Boyle DR; Nower PT; Gao M; Fridell R; Wang C; Hewawasam P; Lopez O; Tu Y; Meanwell NA; Belema M; Roberts SB; Cockett M; Sun JH
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1573-83. PubMed ID: 26711745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones.
    Murayama A; Fujiwara K; Yamada N; Shiina M; Aly HH; Masaki T; Muramatsu M; Wakita T; Kato T
    Antiviral Res; 2018 Oct; 158():161-170. PubMed ID: 30118732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.
    Pham LV; Ramirez S; Gottwein JM; Fahnøe U; Li YP; Pedersen J; Bukh J
    Gastroenterology; 2018 Jun; 154(8):2194-2208.e12. PubMed ID: 29454794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.